Ardelyx

Ardelyx, Inc. is a biopharmaceutical company. engages in the research, development and commercialization of medicine for the treatment of cardiorenal diseases. Its product portfolio includes tenapanor, which is an experimental medication that works exclusively in the gut and is in late-stage clinical development. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet on October 17, 2007 and is headquartered in Fremont, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Ardelyx reports strong Q4 earnings, poised for product expansion

Ardelyx's Q4 performance reflects revenue growth, improved financial efficiency, and progress towards expanding its product portfolio.
While facing challenges such as regulatory processes and market competition, Ardelyx's strengths lie in successful product launches and a proactive commercial strategy.
Opportunities for Ardelyx include leveraging positive feedback for XPHOZAH, raising additional funds for growth, and diversifying revenue through new product launches.

Ardelyx reports sales growth, readies XPHOZAH launch amid challenges

Ardelyx showed strong sales growth for IBSRELA and is poised for the XPHOZAH launch
Financially, the company raised significant funds and maintains a healthy cash position
Challenges include managing expenses and improving profitability amidst losses
Opportunities lie in upcoming product launches and optimizing financial operations

Ardelyx reports strong Q2 performance amidst legislative challenges and growth opportunities

Ardelyx's Q2 performance reflects growth in IBSRELA sales and overall revenue, despite incurring a net loss.
The company faces challenges from pending legislation and financial burdens related to XPHOZAH launch preparation.
Opportunities lie in the potential of XPHOZAH launch, market reception of IBSRELA, and addressing legislative impacts.

Ardelyx reports strong Q3 earnings, poised for successful XPHOZAH launch

Ardelyx's Q3 performance reflects financial strength and positive market reception for IBSRELA.
Challenges in pricing strategy and market competition require strategic planning for XPHOZAH's launch.
Opportunities lie in leveraging financial stability, physician interest, and promotional activities for XPHOZAH success.
The company's commitment to patient access and learnings from IBSRELA will drive future growth and market penetration.

Ardelyx reports strong revenue growth driven by IBSRELA success

Ardelyx is strategically investing in growth, focusing on sustaining momentum for its products. The company is well-resourced and optimistic about the future performance of IBSRELA and XPHOZAH. Despite challenges in operating expenses, Ardelyx remains committed to its commercialization efforts.

Ardelyx reports robust Q1 performance driven by XPHOZAH success

Ardelyx's Q1 2024 earnings call showcased strong revenue growth, particularly driven by XPHOZAH and IBSRELA. The company's cash position remains healthy, and there is a clear focus on expanding market reach and driving adoption of key therapies.

Ardelyx reports robust Q2 earnings, focuses on patient access advocacy

Ardelyx's Q2 2024 performance reflects strong revenue growth driven by IBSRELA and XPHOZAH, with a focus on shareholder value and patient access advocacy. While facing challenges in legal battles and expense management, the company is poised to capitalize on opportunities through sales force expansion and market differentiation strategies.

Ardelyx (ARDX) reports robust Q3 earnings, navigates Medicare coverage challenges

Ardelyx's Q3 earnings call highlighted strong financial performance, success of key medications, and strategies to address Medicare coverage challenges. The company's focus on patient access, commitment to therapy availability, and positive market impact showcase its growth potential and resilience in the market.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

LOS ANGELES, CA / ACCESSWIRE / September 1, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ardelyx, Inc. ("Ardelyx" or "the Company") (NASDAQ:ARDX) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 31, 2023 and July 1, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before October 15, 2024.

A Securities Fraud Lawsuit Has Been Filed Against Ardelyx Inc And Investors Are Encouraged To Play A Part

NEW YORK, Sept. 01, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Ardelyx, Inc. (NASDAQ: ARDX) between October 31, 2023 and July 1, 2024, both dates inclusive (the “Class Period”), of the important October 15, 2024 lead plaintiff deadline.

ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Ardelyx, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ARDX

LOS ANGELES, CA / ACCESSWIRE / August 31, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ardelyx, Inc. ("Ardelyx" or "the Company") (NASDAQ:ARDX) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 31, 2023 and July 1, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before October 15, 2024.

The Schall Law Firm Is Urging Individuals With Losses In Ardelyx Inc. To Contribute To A Case For Securities Law Infractions

Investors can contact the law firm at no cost to learn more about recovering their losses

Ardelyx, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. October 15, 2024 Deadline to file Lead Plaintiff Motion

LOS ANGELES, CA / ACCESSWIRE / August 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ardelyx, Inc. ("Ardelyx" or "the Company") (NASDAQ:ARDX) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 31, 2023 and July 1, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before October 15, 2024.

Ardelyx Inc May Have Engaged In Securities Fraud And Investors Are Invited By The Schall Law Firm To Partake In A Suit

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Ardelyx To Contact Him Directly To Discuss Their Options

DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ardelyx

LOS ANGELES, CA / ACCESSWIRE / August 29, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ardelyx, Inc. ("Ardelyx" or "the Company") (NASDAQ:ARDX) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 31, 2023 and July 1, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before October 15, 2024.

A Lawsuit Has Been Filed Against Ardelyx Inc. For Potential Securities Law Violations And The Schall Law Firm Seeks Stockholders' Assistance

Upcoming Lead Plaintiff Deadline is October 15, 2024 NEW YORK , Aug. 29, 2024 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP  ("Wolf  Haldenstein") announces that a federal securities class action lawsuit has been filed against Ardelyx,Inc. ("Ardelyx" or the "Company") (NASDAQ: ARDX) in the United States District Court for the Districtof Massachusetts on behalf of all persons and entities who purchased or otherwise acquired Ardelyx securities between October 31, 2023 and July 1, 2024, both dates inclusive (the "Class Period"). A ll investors who purchased shares and incurred losses are advised  to contact the firm immediately at classmember@whafh.com  or (800) 575-0735 or (212) 545-4774.

Ardelyx, Inc. Class Action Alert: Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a securities class action lawsuit has been filed in the United States District Court for the District of Massachusetts against Ardelyx, Inc

NEW YORK, Aug. 28, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Ardelyx, Inc. (NASDAQ: ARDX) between October 31, 2023 and July 1, 2024, both dates inclusive (the “Class Period”), of the important October 15, 2024 lead plaintiff deadline.

ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Ardelyx, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ARDX

NEW YORK, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Ardelyx, Inc. ("Ardelyx" or the "Company") (NASDAQ: ARDX) of a class action securities lawsuit.

Ardelyx, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before October 15, 2024 to Discuss Your Rights – ARDX

LOS ANGELES, CA / ACCESSWIRE / August 28, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ardelyx, Inc. ("Ardelyx" or "the Company") (NASDAQ:ARDX) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 31, 2023 and July 1, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before October 15, 2024.

Investors In Ardelyx Inc Are Encouraged To Contact The Schall Law Firm About A Securities Fraud Case

NEW YORK, NY / ACCESSWIRE / August 28, 2024 / If you suffered a loss on your Ardelyx, Inc. (NASDAQ:ARDX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/ardelyx-lawsuit-submission-form?prid=98741&wire=1 or contact Joseph E. Levi, Esq.

Lost Money on Ardelyx, Inc. (ARDX)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky

LOS ANGELES , Aug. 28, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ardelyx, Inc. ("Ardelyx" or "the Company") (NASDAQ: ARDX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 31, 2023 and July 1, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before October 15, 2024.

ARDX Investors Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit with the Schall Law Firm

NEW YORK, Aug. 27, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Ardelyx, Inc. (NASDAQ: ARDX).

The Gross Law Firm Notifies Ardelyx, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline – ARDX

LOS ANGELES, CA / ACCESSWIRE / August 27, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ardelyx, Inc. ("Ardelyx" or "the Company") (NASDAQ:ARDX) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 31, 2023 and July 1, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before October 15, 2024.

Securities Law Infractions Might Have Been Committed By Ardelyx Inc And The Schall Law Firm Is Seeking Shareholders To Assist In A Lawsuit

SAN DIEGO, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Ardelyx, Inc. (NASDAQ: ARDX) securities between October 31, 2023 and July 1, 2024. Ardelyx is a biotechnology company focused on developing and commercializing therapies for, among other things, patients with chronic kidney disease (“CKD”).

ARDX Class Action Notice: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Ardelyx, Inc. Class Action

LOS ANGELES, CA / ACCESSWIRE / August 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ardelyx, Inc. ("Ardelyx" or "the Company") (NASDAQ:ARDX) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 31, 2023 and July 1, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before October 15, 2024.

Ardelyx Inc Is Being Sued For Securities Fraud And Investors Are Invited By The Schall Law Firm To Participate

NEW YORK, NY / ACCESSWIRE / August 26, 2024 / If you suffered a loss on your Ardelyx, Inc. (NASDAQ:ARDX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/ardelyx-lawsuit-submission-form?prid=98090&wire=1 or contact Joseph E. Levi, Esq.

Shareholders that Lost Money on Ardelyx, Inc.(ARDX) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More

NEW YORK , Aug. 26, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Ardelyx, Inc. (NASDAQ: ARDX). Shareholders who purchased shares of ARDX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

Class Action Filed Against Ardelyx, Inc. (ARDX) - October 15, 2024 Deadline to Join - Contact The Gross Law Firm

LOS ANGELES, CA / ACCESSWIRE / August 25, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ardelyx, Inc. ("Ardelyx" or "the Company") (NASDAQ:ARDX) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 31, 2023 and July 1, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before October 15, 2024.

A Case Against Ardelyx Inc For Securities Law Violations Has Been Filed And The Schall Law Firm Seeks Shareholders To Assist

LOS ANGELES, CA / ACCESSWIRE / August 24, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ardelyx, Inc. ("Ardelyx" or "the Company") (NASDAQ:ARDX) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 31, 2023 and July 1, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before October 15, 2024.

Ardelyx Inc Is Being Sued By The Schall Law Firm For Securities Fraud And Investors Can Now Take Part

LOS ANGELES, CA / ACCESSWIRE / August 23, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ardelyx, Inc. ("Ardelyx" or "the Company") (NASDAQ:ARDX) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 31, 2023 and July 1, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before October 15, 2024.

Shareholders With Losses In Ardelyx Inc. Are Urged To Join The Schall Law Firm In Pursuing A Case For Securities Law Violations

NEW YORK, NY / ACCESSWIRE / August 22, 2024 / If you suffered a loss on your Ardelyx, Inc. (NASDAQ:ARDX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/ardelyx-lawsuit-submission-form?prid=97551&wire=1 or contact Joseph E. Levi, Esq.

Class Action Filed Against Ardelyx, Inc. (ARDX) Seeking Recovery for Investors – Contact Levi & Korsinsky

LOS ANGELES, CA / ACCESSWIRE / August 22, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ardelyx, Inc. ("Ardelyx" or "the Company") (NASDAQ:ARDX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 31, 2023 and July 1, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before October 15, 2024.

The Schall Law Firm Invites Ardelyx, Inc. Investors To Participate In A Securities Fraud Suit

NEW YORK , Aug. 22, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Ardelyx, Inc. (NASDAQ: ARDX). Shareholders who purchased shares of ARDX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

News for Ardelyx Stock (ARDX)